Interleukin-12 as an adjuvant for induction of protective antibody responses

Cytokine

Volumn 52, Issue 1-2, 2010, Pages 102-107

  Metzger, Dennis W ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Bacterial infections; Interleukin 12; Mucosal immunity; Vaccine; Viral infections

Indexed keywords

ADJUVANT; GAMMA INTERFERON; IMMUNOGLOBULIN A; INTERLEUKIN 12; BACTERIAL VACCINE; IMMUNOLOGICAL ADJUVANT; VIRUS VACCINE;

ANTIBODY RESPONSE; BACTERIUM; CELLULAR IMMUNITY; DISEASE MODEL; HUMAN; HUMORAL IMMUNITY; LUNG; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TH1 CELL; VIRUS; ANIMAL; ANTIBODY PRODUCTION; BACTERIAL INFECTION; DRUG EFFECT; IMMUNOLOGY; MOUSE; VIRUS INFECTION;

BACTERIA (MICROORGANISMS);

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; BACTERIAL INFECTIONS; BACTERIAL VACCINES; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-12; MICE; TH1 CELLS; VIRAL VACCINES; VIRUS DISEASES;

EID: 79952111785     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.06.011     Document Type: Review

References (52)

1. Pabst R. Is BALT a major component of the human lung immune system?. Immunol Today 1992, 13:119-122.
2. Delventhal S., Hensel A., Petzoldt K., Pabst R. Effects of microbial stimulation on the number, size and activity of bronchus-associated lymphoid tissue (BALT) structures in the pig. Int J Exp Pathol 1992, 73:351-357.
3. Tschernig T., Pabst R. Bronchus-associated lymphoid tissue (BALT) is not present in the normal adult lung but in different diseases. Pathobiology 2000, 68:1-8.
4. Chvatchko Y., Kosco-Vilbois M.H., Herren S., Lefort J., Bonnefoy J.Y. Germinal center formation and local immunoglobulin E (IgE) production in the lung after an airway antigenic challenge. J Exp Med 1996, 184:2353-2360.
5. Moyron-Quiroz J.E., Rangel-Moreno J., Kusser K., Hartson L., Sprague F., Goodrich S., et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med 2004, 10:927-934.
6. Elson C.O., Dertzbaugh M.T. Mucosal adjuvants. Mucosal immunology 2005, 967-986. Elsevier Academic Press, Amsterdam. J. Mestecky, M.E. Lamm, W. Strober, J. Bienenstock, J.R. McGehee, L. Mayer (Eds.).
7. Belyakov I.M., Ahlers J.D. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?. J Immunol 2009, 183:6883-6892.
8. Liang X.P., Lamm M.E., Nedrud J.G. Cholera toxin as a mucosal adjuvant for respiratory antibody responses in mice. Reg Immunol 1989, 2:244-248.
9. Wu H.Y., Russell M.W. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect Immun 1993, 61:314-322.
10. Marinaro M., Staats H.F., Hiroi T., Jackson R.J., Coste M., Boyaka P.N., et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol 1995, 155:4621-4629.
11. Couch R.B. Nasal vaccination, Escherichia coli enterotoxin, and Bell's Palsy. N Engl J Med 2004, 350:860-861.
12. Braun M.C., He J., Wu C.Y., Kelsall B.L. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor β1 and β2 chain expression. J Exp Med 1999, 189:541-552.
13. Gately M.K., Renzetti L.M., Magram J., Stern A.S., Adorini L., Gubler U., et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 1998, 16:495-521.
14. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3:133-146.
15. Bliss J., Van Cleave V., Murray K., Wiencis A., Ketchum M., Maylor R., et al. IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response. J Immunol 1996, 156:887-894.
16. McKnight A.J., Zimmer G.J., Fogelman I., Wolf S.F., Abbas A.K. Effects of IL-12 on helper T cell-dependent immune responses in vivo. J Immunol 1994, 152:2172-2179.
17. Buchanan J.M., Vogel L.A., Van C.V., Metzger D.W. Interleukin 12 alters the isotype-restricted antibody response of mice to hen eggwhite lysozyme. Int Immunol 1995, 7:1519-1528.
18. Metzger D.W., Buchanan J.M., Collins J.T., Lester T.L., Murray K.S., Van Cleave V.H., et al. Enhancement of humoral immunity by interleukin-12. Ann NY Acad Sci 1996, 795:100-115.
19. Germann T., Bongartz M., Dlugonska H., Hess H., Schmitt E., Kolbe L., et al. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b, and IgG3 antibody subclasses in vivo. Eur J Immunol 1995, 25:823-829.
20. Morris S.C., Madden K.B., Adamovicz J.J., Gause W.C., Hubbard B.R., Gately M.K., et al. Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection. J Immunol 1994, 152:1047-1056.
21. Metzger D.W., McNutt R.M., Collins J.T., Buchanan J.M., Van Cleave V.H., Dunnick W.A. IL-12 acts as an adjuvant for humoral immunity through IFN-γ-dependent and IFN-γ-independent mechanisms. Eur J Immunol 1997, 27:1958-1965.
22. Vogel L.A., Showe L.C., Lester T.L., McNutt R.M., Van C.V., Metzger D.W. Direct binding of IL-12 to human and murine B lymphocytes. Int Immunol 1996, 8:1955-1962.
23. Jones D., Elloso M.M., Showe L., Williams D., Trinchieri G., Scott P. Differential regulation of the interleukin-12 receptor during the innate immune response to Leishmania major. Infect Immun 1998, 66:3818-3824.
24. Airoldi I., Gri G., Marshall J.D., Corcione A., Facchetti P., Guglielmino R., et al. Expression and function of IL-12 and IL-18 receptors on human tonsillar B cells. J Immunol 2000, 165:6880-6888.
25. Airoldi I., Cocco C., Giuliani N., Ferrarini M., Colla S., Ognio E., et al. Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target. Blood 2008, 112:750-759.
26. Jelinek D.F., Braaten J.K. Role of IL-12 in human B lymphocyte proliferation and differentiation. J Immunol 1995, 154:1606-1613.
27. Yoshimoto T., Okamura H., Tagawa Y.-I., Iwakura Y., Nakanishi K. Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-γ production from activated B cells. Proc Natl Acad Sci 1997, 94:3948-3953.
28. Thibodeaux D.K., Hunter S.E., Waldburger K.E., Bliss J.L., Trepicchio W.L., Sypek J.P., et al. Autocrine regulation of IL-12 receptor expression is independent of secondary IFN-γ secretion and not restricted to T and NK cells. J Immunol 1999, 163:5257-5264.
29. Skok J., Poudrier J., Gray D. Dendritic cell-derived IL-12 promotes B cell induction of Th2 differentiation: a feedback regulation of Th1 development. J Immunol 1999, 163:4284-4291.
30. Pistoia V., Cocco C., Airoldi I. Interleukin-12 receptor {beta}2: from cytokine receptor to gatekeeper gene in human B-cell malignancies. J Clin Oncol 2009, 27:4809-4816.
31. Airoldi I., Di C.E., Banelli B., Moserle L., Cocco C., Pezzolo A., et al. The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies. J Clin Invest 2004, 113:1651-1659.
32. Gao N., Jennings P., Yuan D. Requirements for the natural killer cell-mediated induction of IgG1 and IgG2a expression in B lymphocytes. Int Immunol 2008, 20:645-657.
33. Yuan D. Interactions between NK cells and B lymphocytes. Advances in immunology 2004, 1-42. Academic Press. W.A. Frederick (Ed.).
34. Buchanan R.M., Arulanandam B.P., Metzger D.W. IL-12 enhances antibody responses to T-independent polysaccharide vaccines in the absence of T and NK cells. J Immunol 1998, 161:5525-5533.
35. Finkelman F.D., Katona I.M., Mosmann T.R., Coffman R.L. IFN-g regulates the isotypes of Ig secreted during in vivo humoral immune responses. J Immunol 1988, 140:1022-1027.
36. Snapper C.M., Paul W.E. Interferon-g and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987, 236:944-947.
37. Finkelman F.D., Svetic A., Gresser I., Snapper C., Holmes J., Trotta P.P., et al. Regulation by interferon alpha of immunoglobulin isotype selection and lymphokine production in mice. J Exp Med 1991, 174:1179-1188.
38. Buchanan R.M., Briles D.E., Arulanandam B.P., Westerink M.A., Raeder R.H., Metzger D.W. IL-12-mediated increases in protection elicited by pneumococcal and meningococcal conjugate vaccines. Vaccine 2001, 19:2020-2028.
39. Lynch J.M., Briles D.E., Metzger D.W. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect Immun 2003, 71:4780-4788.
40. Arulanandam B.P., O'Toole M., Metzger D.W. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis 1999, 180:940-949.
41. Arulanandam B.P., Lynch J.M., Briles D.E., Hollingshead S., Metzger D.W. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun 2001, 69:6718-6724.
42. Sun K., Johansen F.E., Eckmann L., Metzger D.W. An important role for polymeric Ig receptor-mediated transport of IgA in protection against Streptococcus pneumoniae nasopharyngeal carriage. J Immunol 2004, 173:4576-4581.
43. Baron S.D., Singh R., Metzger D.W. Inactivated Francisella tularensis Live Vaccine Strain protects against respiratory tularemia by intranasal vaccination in an IgA-dependent fashion. Infect Immun 2007, 75:2152-2162.
44. Huber V.C., Lynch J.M., Bucher D.J., Le J., Metzger D.W. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 2001, 166:7381-7388.
45. Metzger D.W., Bakshi C.S., Kirimanjeswara G. Mucosal Immunopathogenesis of Francisella tularensis. Ann NY Acad Sci 2007, 1105:266-283.
46. Kirimanjeswara G., Golden J.W., Bakshi C.S., Metzger D.W. Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J Immunol 2007, 179:532-539.
47. Smiley S.T. Current challenges in the development of vaccines for pneumonic plague. Expert Rev Vaccines 2008, 7:209-221.
48. Arulanandam B.P., Van C.V., Metzger D.W. IL-12 is a potent neonatal vaccine adjuvant. Eur J Immunol 1999, 29:256-264.
49. Sabirov A., Metzger D.W. Intranasal vaccination of neonatal mice with polysaccharide conjugate vaccine for protection against pneumococcal otitis media. Vaccine 2006, 24:5584-5592.
50. Cohen J. Clinical trials - IL-12 deaths: explanation and a puzzle. Science 1995, 270:908.
51. Huber V.C., Arulanandam B.P., Arnaboldi P.M., Elmore M.K., Sheehan C.E., Kallakury B.V., et al. Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity. Int Immunopharmacol 2003, 3:801-809.
52. Metzger D.W. IgA and respiratory immunity. Mucosal immune defense: immunoglobulin A 2007, Plenum Publishers, New York. C.S. Kaetzel (Ed.).